Delivery Order SPE2DB20D1100-SPE2DB25FE1D0
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Fluticasone Propionate HFA 110 micrograms in 12-gram inhalers, with a contract value of $24,494.88 and an ultimate completion date of July 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued as a competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive...
- The Defense Logistics Agency awarded a delivery order valued at $1,340.27 to AmerisourceBergen Drug Corp for Fluticasone Propionate HFA 44 micrograms in a 10.6-gram inhaler, with an ultimate completion date of August 11, 2025. This non-competitive, firm fixed-price delivery order was issued on August 8, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Fluticasone Propionate HFA 110 micrograms in 12-gram inhalers, with a ceiling value of $1,504.06. This firm fixed-price delivery order, which was competitively awarded without a set-aside designation, represents a single transaction under AmerisourceBergen's larger pharmaceutical supply framework. The contract specifies Conshohocken, Pennsylvania as the place of...
- The Defense Logistics Agency awarded a delivery order valued at $1,719.68 to AmerisourceBergen Drug Corp for Fluticasone Propionate HFA 44 micrograms in a 10.6-gram inhaler, with delivery performance required by August 6, 2025. This competitive award employs a firm fixed price model and represents a non-set-aside procurement executed on August 5, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Fluticasone Propionate HFA 44 mcg 10.6gm inhalers, valued at $1,257.22. This is a firm fixed price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Fluticasone Propionate HFA 110 micrograms in 12-gram inhalers, valued at $5,930.40. This is a firm fixed price contract with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,075.75 to AmerisourceBergen Drug Corp for Fluticasone Propionate HFA 110 micrograms in 12-gram inhalers. This non-set-aside contract was awarded on August 5, 2025, with an ultimate completion date of August 6, 2025, and operates under firm fixed price terms. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order is issued under...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Fluticasone Propionate HFA 110 micrograms in 12-gram inhalers. This is a firm fixed-price, non-set-aside contract with a ceiling value of $1,051.91 and an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,715.83 on July 29, 2025, for the supply of Fluticasone Propionate HFA 44 microgram inhalers (10.6 grams). This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle running through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order valued at $1,498.25 to AmerisourceBergen Drug Corp for the supply of Fluticasone Propionate HFA 110 micrograms in a 12-gram inhaler. This firm fixed price contract, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1D0Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for Fluticasone Propionate HFA 44 micrograms in a 10.6-gram inhaler, with a ceiling value of $1,288.20 and an ultimate completion date of August 18, 2025. This competitive, firm fixed-price delivery order was issued without a set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply requirements for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026. AmerisourceBergen is a major pharmaceutical distributor and critical federal vendor that supplies an extensive portfolio of pharmaceutical products and medical supplies across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide. The contract vehicle demonstrates the company's capability to meet federal procurement requirements through open competition and its established role as a prime pharmaceutical vendor for military healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 8/15/25 |